Abstract
Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGERAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGEspecific signaling inhibition.
Keywords: diabetic complications, advanced glycation endproducts (age), receptor for age (rage)
Current Drug Targets
Title: Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System
Volume: 6 Issue: 4
Author(s): Khin Mar Myint, Yasuhiko Yamamoto, Shigeru Sakurai, Ai Harashima, Takuo Watanabe, Hui Li, Akihiko Takeuchi, Kazunobu Yoshimura, Hideto Yonekura and Hiroshi Yamamoto
Affiliation:
Keywords: diabetic complications, advanced glycation endproducts (age), receptor for age (rage)
Abstract: Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGERAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGEspecific signaling inhibition.
Export Options
About this article
Cite this article as:
Myint Mar Khin, Yamamoto Yasuhiko, Sakurai Shigeru, Harashima Ai, Watanabe Takuo, Li Hui, Takeuchi Akihiko, Yoshimura Kazunobu, Yonekura Hideto and Yamamoto Hiroshi, Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System, Current Drug Targets 2005; 6 (4) . https://dx.doi.org/10.2174/1389450054021882
DOI https://dx.doi.org/10.2174/1389450054021882 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Fc-fusion Proteins in Therapy: An Updated View
Current Medicinal Chemistry Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus
Current Diabetes Reviews Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Puerarin: A Review on the Pharmacological Activity, Chemical Properties and Pharmacokinetics of Main Isoflavonoid
The Natural Products Journal Central Hemodynamics in Risk Assessment Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Cell-Permeable Peptide Inhibitor of c-Jun NH2-Terminal Kinase for the Treatment of Diabetes
Current Bioactive Compounds Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry Overview of Current and Upcoming Strategies Implied for the Therapy of Type 2 Diabetes Mellitus
Current Diabetes Reviews The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery The Role of the Immune System in the Pathogenesis of Hypertension
Current Hypertension Reviews The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Obesity and Diabetes Gene Discovery Approaches
Current Pharmaceutical Design